BYANNLI®
700 mg, 1000 mg prolonged-release suspension for injection in pre-filled syringe
ACTIVE INGREDIENT(s): 700 mg, 1000 mg paliperidone
Prescribing informationCARVYKTI®▼
3.2 × 106– 1.0 × 108 cells dispersion for infusion
ACTIVE INGREDIENT(s): ciltacabtagene autoleucel
Prescribing informationConcerta® XL Prolonged Release Tablets
ACTIVE INGREDIENT(s): methylphenidate hydrochloride
Prescribing informationDarzalex®
20 mg/ml Concentrate
for Solution for Infusion and 1,800 mg Solution for Injection.
ACTIVE INGREDIENT(s): Daratumumab
Prescribing informationDurogesic® Dtrans®
TRANSDERMAL PATCH
ACTIVE INGREDIENT(s): Fentanyl
Prescribing informationERLEADA®▼
60 mg and 240mg film-coated tablets
ACTIVE INGREDIENT(s): Apalutamide
Prescribing informationIMBRUVICA®
140mg, 280mg, 420mg and 560mg Film-coated Tablets
ACTIVE INGREDIENT(s): ibrutinib
Prescribing informationINVEGA®
PROLONGED RELEASE TABLETS (3 mg, 6 mg and 9 mg)
ACTIVE INGREDIENT(s): paliperidone
Prescribing informationOpsumit®
10mg film-coated tablets
ACTIVE INGREDIENT(s): Macitentan
Prescribing informationPONVORY® ▼
2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 20 mg film-coated tablets
ACTIVE INGREDIENT(s): Ponesimod
Prescribing informationPREZISTA®
100mg/ml oral suspension and 75mg, 150mg, 400mg, 600mg and 800mg film-coated tablets
ACTIVE INGREDIENT(s): Darunavir
Prescribing informationREMICADE®
100 mg powder for concentrate for solution for infusion
ACTIVE INGREDIENT(s): Infliximab
Prescribing informationREZOLSTA®
800 mg/150 mg film-coated tablets
ACTIVE INGREDIENT(s): Darunavir and cobicistat
Prescribing informationRISPERDAL® CONSTA®
25mg, 37.5mg and 50mg injection
ACTIVE INGREDIENT(s): risperidone
Prescribing informationRISPERDAL® Film-Coated Tablets, and Oral Solution
ACTIVE INGREDIENT(s): risperidone
Prescribing informationSIMPONI™
50 mg/0.5 mL solution for injection in pre-filled pen, 50 mg/0.5 mL solution for injection in pre-filled syringe, 100 mg/mL solution for injection in pre-filled pen
ACTIVE INGREDIENT(s): Golimumab
Prescribing informationSPRAVATO®▼
28 mg nasal spray, solution
ACTIVE INGREDIENT(s): Esketamine hydrochloride
Prescribing informationSTELARA®
45 mg and 90 mg solution for injection in pre-filled syringe,
45 mg and 90 mg solution for injection in pre-filled pen,
45 mg solution for injection and
130 mg concentrate for solution for infusion
ACTIVE INGREDIENT(s): ustekinumab
Prescribing informationSYMTUZA®
800 mg/150 mg/200 mg/10 mg film-coated tablets
ACTIVE INGREDIENT(s): darunavir, cobicistat, emtricitabine, tenofovir alafenamide
Prescribing informationTALVEY®▼
2 mg/mL and 40 mg/mL solution for injection
ACTIVE INGREDIENT(s): talquetamab
Prescribing informationTremfya®
100 mg solution for injection in pre-filled pen
ACTIVE INGREDIENT(s): Guselkumab
Prescribing informationTREVICTA®
175 mg, 263 mg, 350 mg & 525 mg prolonged release suspension for injection
ACTIVE INGREDIENT(s): paliperidone
Prescribing informationUPTRAVI®
200-1600 µg film-coated tablets
ACTIVE INGREDIENT(s): Selexipag
Prescribing informationVELCADE®
3.5 mg powder for solution for injection
ACTIVE INGREDIENT(s): bortezomib
Prescribing informationVELETRI®
0.5mg and 1.5mg, powder for solution for infusion
ACTIVE INGREDIENT(s): Epoprostenol
Prescribing informationXEPLION®
50 mg, 75 mg, 100 mg & 150 mg prolonged release suspension for injection
ACTIVE INGREDIENT(s): paliperidone
Prescribing informationZYTIGA®
500 mg film-coated tablets
ACTIVE INGREDIENT(s): abiraterone acetate
Prescribing informationDarzalex®
20 mg/ml Concentrate
for Solution for Infusion and 1,800 mg Solution for Injection.
3.5 mg powder for solution for injection
in combination withACTIVE INGREDIENT(s): Daratumumab and bortezomib and
Prescribing informationXEPLION®
50 mg, 75 mg, 100 mg & 150 mg prolonged release suspension for injection
TREVICTA®175 mg, 263 mg, 350 mg & 525 mg prolonged release suspension for injection
BYANNLI®700 mg, 1000 mg prolonged-release suspension for injection in pre-filled syringe
ACTIVE INGREDIENT(s): paliperidone
Prescribing information